# BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy

> **NCT05250895** · EARLY_PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 9 (actual)

## Conditions studied

- BCLC Stage a Hepatocellular Carcinoma
- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Hepatocellular Carcinoma

## Interventions

- **OTHER:** 18F-Fluoromisonidazole
- **PROCEDURE:** Biopsy
- **PROCEDURE:** Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT05250895
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-04-28
- **Primary completion:** 2025-02-26
- **Final completion:** 2025-02-26
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05250895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05250895, "BOLD MRI and FMISO PET for the Assessment of Hypoxic Tumor Microenvironment in Patients with Oligometastatic Liver Cancer Undergoing Yttirum-90 Selective Internal Radiation Therapy". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT05250895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*